We are a global biopharmaceutical company whose mission is to discover, develop, and deliver innovative medicines that help patients prevail over serious diseases.
Working Together For Patients
Patients are at the center of everything we do.
ristol-Myers Squibb is a differentiated company, led by our unique BioPharma strategy that leverages the reach and resources of a major pharma company paired with the entrepreneurial spirit and agility of a biotech firm. We work every day to deliver innovative medicines for patients with serious and life-threatening diseases.
Each day, our employees around the world work together for patients—it drives everything we do. We are focused on helping millions of patients around the world in disease areas such as oncology, cardiovascular, immunoscience, and fibrosis. Through our Research & Development organization, we have built a sustainable pipeline of potential therapies, and actively partner to access external innovation to broaden and accelerate our work.
As global citizens, we work sustainably and responsibly and seek to give back. Through the Bristol-Myers Squibb Foundation, we promote health equity and strive to improve health outcomes of populations disproportionately affected by serious diseases and conditions, giving new hope to some of the world’s most vulnerable people.
About Bristol-Myers Squibb Australia
With an Australian presence dating back more than 80 years, Bristol-Myers Squibb Australia is a longstanding contributor to Australia’s health and economy.
Some 300 employees are part of the team at BMS Australia, with just over half of the group located at the company’s headquarters in Mulgrave, a suburb located 13 miles south-east of Melbourne. Our organisation provides a diverse, inclusive and flexible working environment. In 2017, we were certified by the Great Place to Work® Institute.
We play an integral part in Australian clinical research with a local and global impact – currently conducting 60 trials at over 200 sites involving 1,200 patients. These trials focus on Oncology, Cardiovascular and Immunology.
We are an active member of Medicines Australia, the pharmaceutical industry body, and are committed to upholding the Medicines Australia Code of Conduct and maintaining transparency through regular disclosure of information. Our values are rooted in a steadfast commitment to the highest standards of quality, uncompromising ethics, compliance and integrity. They are central to who we are, what we do and how we do it.
The Bristol Myers Squibb company we know today has a proud heritage involving two companies – Bristol-Myers and ER Squibb – that began operating more than 100 years ago.
Based in New York City, USA, the Bristol-Myers company began in 1887 when two friends – William McLaren Bristol and John Ripley Myers - founded a small manufacturing company that sold medicines directly to doctors. Even earlier, in 1858, industry pioneer Dr Edward Robinson Squibb formed a pharmaceutical company that would eventually bear his name for years to come, ER Squibb & Sons
During World War II, both Bristol-Myers and Squibb developed manufacturing processes to mass- produce penicillin. In the early 1960s, Bristol-Myers developed its first anti-cancer medicine, which is still used for treatment today.
In 1989, Squibb and Bristol Myers merged, forming the modern company that is now known as Bristol-Myers Squibb.
In Australia during 1967, the Prime Minister Rt. Hon. Harold Holt officially opened the company’s manufacturing plant in the Melbourne suburb of Noble Park (known then as E.R Squibb and Sons Pty Ltd). The Australian company remained at this site until 2012, when the business shifted its headquarters to the current Mulgrave location.
About Bristol-Myers Squibb Australia
Bristol-Myers Squibb Foundation
Corporate Leadership Team